Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis

D M Paton
Drugs of Today 2018, 54 (7): 433-444
Tildrakizumab is a monoclonal antibody that binds to the p19 subunit of interleukin (IL)-23. Studies examining affected skin in psoriatic patients showed significant changes in the cellular, cytokine and gene expression profiles of psoriatic lesions as a result of treatment with tildrakizumab, as well as significant changes in clinical measures of disease activity. These studies demonstrated significant clinical responses in psoriasis with significant improvements found in the percentage of patients achieving a Physician Global Assessment score of 0 or 1, and a 75%, 90% or 100% improvement in the Psoriasis Area and Severity Index (PASI 75, PASI 90, PASI 100). These changes were accompanied by a low frequency of adverse effects. This combination of efficacy and safety led to the approval of tildrakizumab in 2018 by the U.S. Food and Drug Administration (FDA) for use in adult patients with moderate to severe psoriasis.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"